Merck & Co Inc. (NYSE:MRK) on Wednesday released topline data from the Phase 3 KEYNOTE‑C93 trial of Keytruda (pembrolizumab).

benzinga.com - 2026-07-15 13:25:15

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026.

businesswire.com - 2026-07-15 07:00:00

Merck's Keytruda in combination with Pfizer's Padcev wins FDA nod for expanded use in muscle-invasive bladder cancer, regardless of cisplatin eligibility.

zacks.com - 2026-07-13 12:11:04

Merck & Co. Inc. (NYSE:MRK) shares are in focus Monday after a wave of analyst activity capped by a new FDA approval for its cancer drug Keytruda.

benzinga.com - 2026-07-13 08:20:39

In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.

zacks.com - 2026-07-10 18:46:03

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Merck's anti-PD-1 therapies, each in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for the treatment of adult patients with muscle-invasive bla.

businesswire.com - 2026-07-10 14:10:00

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

zacks.com - 2026-07-10 09:56:23

Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

zacks.com - 2026-07-09 10:01:04

VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.

fool.com - 2026-07-09 08:15:04

MRK trades above its 50- and 200-day SMAs as pipeline progress, acquisitions and Keytruda strength offset patent and vaccine headwinds.

zacks.com - 2026-07-08 09:26:06

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

benzinga.com - 2026-07-08 08:40:20

This dividend ETF's focus beyond yield continues to pay off for investors.

fool.com - 2026-07-07 05:30:00

Merck (MRK) concluded the recent trading session at $126.78, signifying a -2.15% move from its prior day's close.

zacks.com - 2026-07-06 18:50:17

The YieldMax MSTR Option Income Strategy ETF (NYSEARCA:MSTY) is the single-stock income product retail investors flocked to when MicroStrategy (now Strategy) was climbing alongside Bitcoin.

247wallst.com - 2026-07-05 11:39:31

On July 02, 2026, Merck and Co Inc (MRK) shares rose 3.3% today, currently priced at $129.56. The stock has experienced significant price appreciation, trading wi

gurufocus.com - 2026-07-02 17:17:00

Merck stock is in a buy zone after hitting a new high. Fellow Dow stock JPMorgan Chase and Amphenol are both trading around entry points.

investors.com - 2026-07-02 14:04:38

Portfolio concentration and sector weightings set these two popular income funds apart for investors seeking steady cash flow.

fool.com - 2026-07-01 07:45:01

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4.

businesswire.com - 2026-07-01 06:45:00

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country's military capabilities, according to a Reuters report. The inquiry, led by Republican Representative John Moolenaar of Michigan, chair of the House Select Committee on China, focuses on whether the drugmakers conducted adequate due diligence and maintained sufficient data protection standards at trial sites in China.

proactiveinvestors.com - 2026-06-30 12:35:12

Stock futures are pointed lower to end the month and quarter as AI capex concerns linger

schaeffersresearch.com - 2026-06-30 09:08:00

A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...

proactiveinvestors.com - 2026-06-30 08:19:00

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?

fool.com - 2026-06-30 07:45:03

Merck extends its bullish breakout from a pennant pattern, supported by strong volume and higher swing lows, with technical structure pointing toward continued upside potential.

fxempire.com - 2026-06-29 17:08:28

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

zacks.com - 2026-06-29 10:31:05

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck Announces Agreement to Improve Treatment Access for People Living with HIV. Agreement will help state ADAP programs provide access to IDVYNSO.

businesswire.com - 2026-06-29 06:45:00

Merck (MRK) closed the most recent trading day at $128.66, moving +2.56% from the previous trading session.

zacks.com - 2026-06-26 18:45:24

Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.

zacks.com - 2026-06-26 10:01:09

On CNBC's “Halftime Report Final Trades,” Jim Lebenthal, partner and chief market strategist at Cerity Partners, named Qualcomm Incorporated (NASDAQ:QCOM) as his final trade.

benzinga.com - 2026-06-26 07:32:39

Dan Deming talks joins today's Big 3 and highlights JPMorgan Chase (JPM) as shares touch new record highs. He sees Danaher (DHR) as a candidate for a continuing breakout, noting a similar pattern in Merck (MRK).

youtube.com - 2026-06-25 13:00:07

Merck wins EU approval for Keytruda plus Padcev in patients with resectable muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.

zacks.com - 2026-06-25 11:06:08

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), each in combination with Trodelvy® (sacituzumab govitecan-hziy), Gilead's Trop-2-directed antibody-drug conjugate (ADC), for the first-line treatment of adult patients with unresectable locally advanced or metastatic triple-negative.

businesswire.com - 2026-06-25 06:45:00

Gilead secures EC approval to expand Trodelvy into first-line metastatic TNBC, marking a new treatment option and broadening its oncology reach.

zacks.com - 2026-06-24 12:25:28

Pre-Market Stock Futures: Futures are trading higher this morning, but if you've ever heard the old saying, "when the chips are down", that was the poster child phrase for Tuesday's session, as technology stocks, and specifically the semiconductor stocks, followed a worldwide sell-off that initially began in Korea and carried around the globe. When... Here Are Wednesday's Best Wall Street Analyst Research Calls: Devon Energy, Flowserve, Klaviyo, Macerich, Merck, Nucor, Take-Two Interactive Software, Twilio, and More

247wallst.com - 2026-06-24 08:15:12

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in combination with Padcev® (enfortumab vedotin-ejfv), an antibody-drug conjugate (ADC), is approved in the European Union (EU), as neoadjuvant treatment and then continued after radical cystectomy (RC) as adjuvant treatment, for adults with resectable muscle-invasive bladder cancer (MIBC) who are ineligible for cispla.

businesswire.com - 2026-06-24 06:45:00

Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key colorectal cancer subgroup, raising approval uncertainty.

zacks.com - 2026-06-23 15:26:06

MRK's tulisokibart meets goals in a late-stage ulcerative colitis study, strengthening a key pipeline asset as the company looks beyond Keytruda.

zacks.com - 2026-06-23 12:46:12

NEW YORK--(BUSINESS WIRE)--Merck, through the company's Merck for Mothers initiative, and Mae are collaborating on a multi-state effort to expand and sustain the community-based doula workforce, with a goal of advancing maternal health equity and access for those experiencing the most disparate outcomes. The collaboration will advance doula training, professional development, and ongoing administrative support towards Medicaid participation for community doulas. It will also allow Mae to extend.

businesswire.com - 2026-06-23 10:00:00

Bank of America has predicted that the Federal Reserve will be forced to raise interest rates by 75 basis points this year, with the first 25-basis-point hike in September.

247wallst.com - 2026-06-23 08:40:05

ABBV's successful transition beyond Humira and growth from newer medicines give it an edge over MRK in this oncology-immunology showdown.

zacks.com - 2026-06-22 10:56:14

I continue to believe that Merck & Co., Inc. has an attractive risk/reward profile. Ten days ago, on June 12, the FDA approved both Keytruda and Keytruda Qlex in combination with Welireg for the treatment of a type of kidney cancer called earlier-stage ccRCC. Overall, this "trio" generated $8.23 billion in sales for Merck in Q1, up 12.1% year-over-year.

seekingalpha.com - 2026-06-22 10:33:59

Merck ​said on ‌Monday its ​drug ​met the ⁠main ​goal in ​a late-stage trial ​testing ​it in ‌patients ⁠with a type ​of ​inflammatory ⁠bowel disease.

reuters.com - 2026-06-22 07:16:10

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the Phase 3 ATLAS-UC induction-only study (Study 2) evaluating tulisokibart (MK-7240), an investigational humanized monoclonal antibody targeting tumor necrosis factor-like cytokine 1A (TL1A), in patients with moderately to severely active UC. The study successfully met its primary endpoint of clinical remission according to the Modified Mayo Scor.

businesswire.com - 2026-06-22 06:45:00

In the closing of the recent trading day, Merck (MRK) stood at $113.87, denoting a -1.36% move from the preceding trading day.

zacks.com - 2026-06-18 18:51:20

The U.S. FDA on Thursday approved an expanded indication for Merck & Co Inc.'s (NYSE:MRK) Capvaxive, extending its use to children and adolescents ages 2–17 with chronic conditions who have completed a primary pneumococcal vaccine series.

benzinga.com - 2026-06-18 11:29:26

Drugmaker Merck said on Thursday the U.S. health regulator has approved an expanded use of its ​pneumococcal vaccine for children and teenagers who ‌face a higher risk of catching the bacterial disease due to chronic health conditions.

reuters.com - 2026-06-18 06:45:48

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Approves an Additional Indication for CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine).

businesswire.com - 2026-06-18 06:45:00

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced results from a new global survey of dog owners and veterinarians revealing challenges and pain points associated with diagnosing the underlying cause of allergic skin disease in dogs and its treatment. According to Pet Owner and Vet Perspectives on Canine Pruritus: A Global Survey, about one-thi.

businesswire.com - 2026-06-17 06:45:00

Gilead seeks FDA approval for once-weekly oral Yeztugo for HIV prevention, aiming to expand access with a new long-acting PrEP option.

zacks.com - 2026-06-16 15:21:19

CARLSBAD, Calif.--(BUSINESS WIRE)--Protillion Biosciences, Inc., a leader in lab-in-the-loop AI drug design, today announced the signing of a multi-target discovery collaboration and license agreement with Merck, known as MSD outside the United States and Canada. The agreement combines Protillion's proprietary platform with Merck's global expertise in the discovery of novel therapeutic candidates. “Merck is a global leader in biopharmaceutical innovation, making them an ideal partner to deploy.

businesswire.com - 2026-06-16 08:00:00

Merck is a buy-the-dip opportunity after a pullback to $114.90, offering a compelling entry for value and income investors. MRK's robust pipeline, including 20 potential blockbusters and strategic acquisitions like Terns, positions it to bridge the Keytruda patent cliff. Normalized forward P/E of 12.0 and 3% dividend yield support a favorable risk/reward profile.

seekingalpha.com - 2026-06-16 07:15:08